About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Ovarian Cancer Clinical Trials in Pittsburgh | 220 Studies

Clinical Trials Ovarian CancerPittsburgh

Ovarian Cancer Clinical Trials in Pittsburgh

Find 220 clinical trials for ovarian cancer near Pittsburgh, Pennsylvania. Connect with research centers in your area.

All Ovarian Cancer trials nationwide All trials in Pittsburgh

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 61-80 of 220 trials

CompletedEP0057 in Combination With Olaparib in Advanced Ovarian CancerEP0057-201 is a Phase 2A/B adaptive design study.NCT04669002·Irvine, California and 20 others Active not recruitingTesting the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian CancerThis phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a…NCT02345265·Phoenix, Arizona and 19 others

Ovarian Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerThis trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas.NCT04254107·Birmingham, Alabama and 35 others

Active not recruitingOregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryStudy to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel…NCT04498117·Phoenix, Arizona and 147 others

TerminatedCB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsThe purpose of this protocol is to investigate the efficacy of the combination of CB-839 with Niraparib in platinum resistant BRCA wild-type ovarian cancer patients.NCT03944902·Birmingham, Alabama and 3 others

Active not recruitingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerThis phase I trial studies the side effects and best dose of peposertib when given together with pegylated liposomal doxorubicin hydrochloride in treating patients with high or…NCT04092270·Aurora, Colorado and 10 others

Active not recruitingTesting the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian CancerThis randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating…NCT02502266·Birmingham, Alabama and 397 others

CompletedGlycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.NCT05259696·La Jolla, California and 12 others

Active not recruitingNivolumab and Ipilimumab in Treating Patients With Rare TumorsThis phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors.NCT02834013·Birmingham, Alabama and 1006 others

UnknownPhase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor…NCT02584478·Long Beach, California and 40 others

CompletedA Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)The purpose of this phase 3, randomized, multicenter study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with Recurrent Platinum-Resistant…NCT03398655·Birmingham, Alabama and 93 others

RecruitingA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043·Grand Rapids, Michigan and 12 others

CompletedCarboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerThis randomized phase III trial studies carboplatin, paclitaxel, and bevacizumab to see how well they work compared to carboplatin, paclitaxel, and placebo in treating patients…NCT00262847·Anniston, Alabama and 631 others

CompletedTLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian CancerThe purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat…NCT00057720·Little Rock, Arkansas and 319 others

UnknownCombination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal CancerRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00017303·Glendale, California and 18 others

Active not recruitingStudy of INCB123667 in Subjects With Advanced Solid TumorsThis is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when…NCT05238922·Duarte, California and 40 others

CompletedTLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian CancerThe purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have…NCT00102973·Little Rock, Arkansas and 221 others

RecruitingA Study of Lorigerlimab in Participants With Advanced Solid TumorsStudy CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC).NCT06730347·Los Angeles, California and 15 others

WithdrawnZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid TumorsThis Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent…NCT06161493·Pittsburgh, Pennsylvania

RecruitingTesting Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerThis phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination…NCT06580314·Birmingham, Alabama and 708 others

PreviousPage 4 of 11Next

Other Conditions in Pittsburgh

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia